Immunotherapy combo shows promise in aggressive breast cancer trial

NCT ID NCT02883062

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (carboplatin and paclitaxel) before surgery helps shrink tumors in people with stage II-III triple negative breast cancer. About 67 participants will receive either chemo alone or chemo plus atezolizumab. The study measures how many patients have no cancer left at surgery and looks at immune cell changes in the tumor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab (Tecentriq) plus carboplatin and paclitaxel
What this could lead to: If it works, this could lead to a more effective treatment for triple negative breast cancer, potentially increasing the chance of eliminating the tumor before surgery.
What could go wrong: This is a small, early-phase trial with only 67 participants, so results may not apply to everyone. Adding immunotherapy can cause serious side effects, and it's not yet proven to be better than chemo alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INVASIVE BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm invasive breast carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INVASIVE BREAST CARCINOMA STAGE II BREAST CANCER AJCC V6 AND V7 STAGE III BREAST CANCER AJCC V7 TRIPLE-NEGATIVE BREAST CARCINOMA

Contacts and locations

Locations

Duke University Medical Center

Durham, North Carolina, 27710, United States
Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287, United States
Mayo Clinic Hospital in Arizona

Phoenix, Arizona, 85054, United States
Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States
Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Siteman Cancer Center at Christian Hospital

St Louis, Missouri, 63136, United States
Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, 63376, United States
Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141, United States
Siteman Cancer Center-South County

St Louis, Missouri, 63129, United States
UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.